Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient [18]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 10, 2007, Pages 1434-1435

  Tavares Bello, R ^a,b  

^a Hospital Militar de Belem   (Portugal)

^b NONE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EMOLLIENT AGENT; PYRIDOXINE; TACROLIMUS;

AGED; CASE REPORT; CAUCASIAN; COLON ADENOCARCINOMA; DRUG RESPONSE; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HEMICOLECTOMY; HUMAN; HYPERPIGMENTATION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTECTIVE CLOTHING; SKIN CARE; SKIN EDEMA; SKIN EXFOLIATION; VITILIGO;

ADENOCARCINOMA; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DIAGNOSIS, DIFFERENTIAL; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; HYPERPIGMENTATION; MALE; VITILIGO;

EID: 35648974767     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02242.x     Document Type: Letter

References (6)

1. Litt JZ. Drug eruptions. In: Litt JZ, ed. Drug Eruption Reference Manual. DERM, Parthenon Publishing Group, London, 2001: 44-45.
2. Carmi E, Gras V. Syndrome pied-main pigmentéàla capécitabine (Xeloda®). Nouvel Dermatol 2005; 24: 185-186.
3. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-800.
4. Pui JC, Meehan S, Moskovits T. Capecitabine induced cutaneous hyperpigmentation: Report of a case. J Drugs Dermatol 2002; 1: 202-205,.
5. Bafounta M, Vaillant J, Lepére C. et al. Toxidermies photodéclenchées au Xeloda® (capécitabine). Ann Dermatol Vénéréol 2004; 131: 1S, 264.
6. Revuz J, Valeyrie-Allanore L. Drug reactions. In: Bolognia JL, Jorizzo JL, Rapini RP, et al., eds. Dermatology. Mosby, Edinburgh, 2002: 333-353.